Technical Analysis for STRO - Sutro Biopharma, Inc.

Grade Last Price % Change Price Change
grade F 8.85 1.72% 0.15
STRO closed up 1.72 percent on Monday, August 19, 2019, on 47 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical STRO trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New Downtrend Bearish 1.72%
Spinning Top Other 1.72%
Lower Bollinger Band Walk Weakness 1.72%
Wide Bands Range Expansion 1.72%
Oversold Stochastic Weakness 1.72%
Jack-in-the-Box Bearish Bearish Swing Setup 3.39%
Stochastic Buy Signal Bullish 3.39%

Older signals for STRO ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Medicine Cancer Clinical Medicine Immunology California Antibodies Drug Discovery Cancer Treatments Antineoplastic Drugs Multiple Myeloma Sutro Biopharma Autoimmune Disorders Non Hodgkin Lymphoma Adc Immunogen South San Francisco Therapeutics For Cancer Milatuzumab
Is STRO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 15.9
52 Week Low 8.34
Average Volume 48,028
200-Day Moving Average 10.7468
50-Day Moving Average 11.0076
20-Day Moving Average 10.2265
10-Day Moving Average 9.387
Average True Range 0.5762
ADX 26.65
+DI 11.3863
-DI 29.9726
Chandelier Exit (Long, 3 ATRs ) 10.0714
Chandelier Exit (Short, 3 ATRs ) 10.0686
Upper Bollinger Band 12.2059
Lower Bollinger Band 8.2471
Percent B (%b) 0.15
BandWidth 38.711192
MACD Line -0.6665
MACD Signal Line -0.4835
MACD Histogram -0.1829
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.65
Resistance 3 (R3) 9.67 9.42 9.51
Resistance 2 (R2) 9.42 9.22 9.41 9.47
Resistance 1 (R1) 9.14 9.10 9.12 9.12 9.42
Pivot Point 8.89 8.89 8.88 8.88 8.89
Support 1 (S1) 8.61 8.69 8.59 8.59 8.28
Support 2 (S2) 8.36 8.57 8.35 8.23
Support 3 (S3) 8.08 8.36 8.19
Support 4 (S4) 8.06